🆕Recommendation provided by Pharmacovigilance Risk Assessment Committee (#PRAC) about Janus kinase inhibitors #JAKi ⏩EMA recommends measures to minimise risk of serious side effects with #JAKi for chronic inflammatory disorders. https://t.co/YqaX7UxtUA https://t.co/dCJbqanAxF